FDA Panel Okays Pfizer Vax For Children Ages 5-11

The New York Times reports:

A key advisory committee to the Food and Drug Administration voted overwhelmingly to recommend the use of Pfizer-BioNTech’s coronavirus vaccine in 5- to 11-year-olds, bringing the vaccine a big step closer to about 28 million children. Shots could be offered as early as next week.

The panel endorsed giving the age group one-third of the dosage given to people 12 and older in two shots, three weeks apart. The committee’s recommendations on whether to authorize vaccines are not binding, but the F.D.A. typically follows them in the days after the vote.

That will turn the matter over to the C.D.C., which has its own expert panel scheduled to weigh in next week.

Read the full article.

BREAKING: FDA advisers endorse Pfizer’s COVID-19 vaccine for children ages 5 to 11. The FDA isn’t bound by the recommendation and is expected to make a decision within days. The kid-sized dose is a third of the Pfizer shot that adults received. https://t.co/nUN6781Y23

— The Associated Press (@AP) October 26, 2021

Breaking News: A key FDA advisory panel recommended the use of the Pfizer coronavirus vaccine in 5- to 11-year-olds, who could start getting shots late next week. https://t.co/tUa7p3KzSp pic.twitter.com/AmO0ymq7Ok

— The New York Times (@nytimes) October 26, 2021